American Oriental Bioengineering Inc (AOB) Financial Statements (2024 and earlier)

Company Profile

Business Address NO, 4018 JINTIAN ROAD, ANLIAN PLAZA
FUTIAN, DISTRICT SHENZHEN, 518026
State of Incorp. CO
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2013
MRQ
12/31/2012
12/31/2011
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 7,097
Cash and cash equivalents 7,097
Receivables 45,544
Inventory, net of allowances, customer advances and progress billings20,571
Inventory 20,571
Prepaid expense 227
Advances on inventory purchases 10,065
Other current assets 719
Other undisclosed current assets 11,225
Total current assets: 95,448
Noncurrent Assets
Property, plant and equipment 171,381
Long-term investments and receivables 3,337
Long-term investments 3,337
Intangible assets, net (including goodwill)145,315
Intangible assets, net (excluding goodwill) 145,315
Deferred costs 267
Other undisclosed noncurrent assets 30,560
Total noncurrent assets: 350,860
TOTAL ASSETS: 446,309
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 28,107
Taxes payable 763
Accounts payable 11,005
Accrued liabilities 16,339
Debt 6,873
Other undisclosed current liabilities 71,231
Total current liabilities: 106,212
Noncurrent Liabilities
Long-term debt and lease obligation 555
Long-term debt, excluding current maturities 555
Liabilities, other than long-term debt 11,956
Deferred tax liabilities, net 11,956
Total noncurrent liabilities: 12,511
Total liabilities: 118,722
Equity
Equity, attributable to parent, including: 327,587
Preferred stock 1
Common stock 73
Treasury stock, value (800)
Additional paid in capital 177,974
Accumulated other comprehensive income 71,790
Retained earnings 78,098
Other undisclosed equity, attributable to parent 451
Total equity: 327,587
TOTAL LIABILITIES AND EQUITY: 446,309

Income Statement (P&L) ($ in thousands)

9/30/2013
TTM
12/31/2012
12/31/2011
Revenues 145,100
Cost of revenue (100,742)
Gross profit: 44,358
Operating expenses (130,689)
Operating loss: (86,331)
Nonoperating income
(Other Nonoperating income)
 379
Interest and debt expense 36,138
Loss from continuing operations before equity method investments, income taxes: (49,814)
Loss from equity method investments (2,813)
Other undisclosed loss from continuing operations before income taxes (4,874)
Loss from continuing operations before income taxes: (57,501)
Income tax expense (2,224)
Loss from continuing operations: (59,725)
Loss before gain (loss) on sale of properties: (59,725)
Net loss: (59,725)
Net income attributable to noncontrolling interest 12
Net loss available to common stockholders, diluted: (59,713)

Comprehensive Income ($ in thousands)

9/30/2013
TTM
12/31/2012
12/31/2011
Net loss: (59,725)
Comprehensive loss: (59,725)
Comprehensive loss, net of tax, attributable to noncontrolling interest (12)
Other undisclosed comprehensive income, net of tax, attributable to parent 4,092
Comprehensive loss, net of tax, attributable to parent: (55,646)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: